Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1

Characterization of health concerns in people with neurofibromatosis type 1

(2022) Jane Fleming et al.   Molecular Genetics & Genomic Medicine

Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial

(2021) Michael J. Fisher et al.   NATURE MEDICINE

FDA Approval Summary: Selumetinib for Plexiform Neurofibroma

(2021) Denise Casey et al.   CLINICAL CANCER RESEARCH

NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas

(2021) Brian D. Weiss et al.   JOURNAL OF CLINICAL ONCOLOGY

Trametinib for orbital plexiform neurofibromas in young children with neurofibromatosis type 1

(2021) Helen Toledano et al.   CHILDS NERVOUS SYSTEM

LC–MS/MS bioanalytical method for quantification of binimetinib and venetoclax, and their pharmacokinetic interaction

(2021) Anuradha Reddy et al.   Bioanalysis

Selumetinib in Children with Inoperable Plexiform Neurofibromas

(2020) Andrea M. Gross et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1

(2018) Andrea M Gross et al.   NEURO-ONCOLOGY

Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas

(2016) Eva Dombi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas

(2009) A. Kim et al.   NEUROLOGY

Three new datasets supporting use of the Numerical Rating Scale (NRS-11) for children’s self-reports of pain intensity

(2009) Carl L. von Baeyer et al.   PAIN